IRON DEFICIENCY ANEMIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On March 20, 2024, Cadila Pharmaceuticals, a global pharmaceutical company, announced the launch of iron supplement injection, for the treatment of iron deficiency anemia
• In July 2021, Sandoz, a global leader in generic and biosimilar medicines, announced the immediate U.S. availability of generic Ferumoxytol, an intravenous medicine used to treat iron deficiency anemia (IDA)
• In May 2021, American Regent, Inc., a Daiichi Sankyo Group company, announced that the U.S. Food and Drug Administration (FDA) had approved a single 1000 mg dose option of Injectafer (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD)
• In May 2020, Akebia Therapeutics., a pharmaceutical company, in collaboration with Japan Tobacco, Inc., a Japan-based tobacco company, filed a supplemental New Drug Application (NDA) with the Pharmaceuticals and Medical Devices Agency (PMDA) seeking an additional indication for Riona Tablets 250mg (generic name in Japan: ferric citrate hydrate) to treat adult patients with iron deficiency anemia (IDA) in Japan